These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 7586663)

  • 1. Response to L-dopa and evolution of motor fluctuations in the early phase of treatment of Parkinson's disease.
    Shif M; Kempster PA
    Clin Exp Neurol; 1994; 31():38-42. PubMed ID: 7586663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease.
    McColl CD; Reardon KA; Shiff M; Kempster PA
    Mov Disord; 2002 Nov; 17(6):1227-34. PubMed ID: 12465061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa in the early treatment of Parkinson's disease.
    Murata M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S17-20. PubMed ID: 19131036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.
    Kum WF; Gao J; Durairajan SS; Man SC; Xie LX; Lu JH; Fong WL; Li M
    J Clin Neurosci; 2009 Aug; 16(8):1034-7. PubMed ID: 19428256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.
    Mazzella L; Yahr MD; Marinelli L; Huang N; Moshier E; Di Rocco A
    Parkinsonism Relat Disord; 2005 May; 11(3):151-5. PubMed ID: 15823479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
    Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
    Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Motor complications in patients with Parkinson disease treated with levodopa].
    Luquin MR; Obeso JA; Martínez-Lage JM
    Neurologia; 1989; 4(1):4-11. PubMed ID: 2631806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients].
    Vaamonde J; Ibáñez R; Gudín M; Hernández A
    Neurologia; 2003 Apr; 18(3):162-5. PubMed ID: 12677484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I.
    Fabbrini G; Mouradian MM; Juncos JL; Schlegel J; Mohr E; Chase TN
    Ann Neurol; 1988 Sep; 24(3):366-71. PubMed ID: 3228270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].
    Maurel F; Lilliu H; Le Pen C
    Rev Neurol (Paris); 2001 May; 157(5):507-14. PubMed ID: 11438770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Levodopa and controlled release benserazide in the handling of motor fluctuations in Parkinson's disease].
    Díaz F; Chaná P
    Rev Med Chil; 1991 Sep; 119(9):1022-8. PubMed ID: 1845094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of early dopa treatment in Parkinson's disease.
    Markham CH; Diamond SG
    Ann Neurol; 1986 Apr; 19(4):365-72. PubMed ID: 3707088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal study of the motor response to levodopa in Parkinson's disease.
    Clissold BG; McColl CD; Reardon KR; Shiff M; Kempster PA
    Mov Disord; 2006 Dec; 21(12):2116-21. PubMed ID: 17029259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acoustic analysis of parkinsonian speech II: L-Dopa related fluctuations and methodological issues.
    Goberman AM; Coelho C
    NeuroRehabilitation; 2002; 17(3):247-54. PubMed ID: 12237506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease.
    Lee WY; Yoon WT; Shin HY; Jeon SH; Rhee PL
    Mov Disord; 2008 Sep; 23(12):1696-700. PubMed ID: 18649391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.
    Mouradian MM; Juncos JL; Fabbrini G; Schlegel J; Bartko JJ; Chase TN
    Ann Neurol; 1988 Sep; 24(3):372-8. PubMed ID: 3228271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison between L-dopa and lisuride intravenous infusions: a clinical study.
    Ruggieri S; Stocchi F; Carta A; Bravi D; Bragoni M; Giorgi L; Agnoli A
    Mov Disord; 1988; 3(4):313-9. PubMed ID: 3211176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Motor fluctuations in Parkinson disease: risk factors].
    Grandas F; Luquin MR; Rodríguez M; Vaamonde J; Lera G; Obeso JA
    Neurologia; 1992 May; 7(5):89-93. PubMed ID: 1389297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.